Hepatitis B immune globulin
Identification
- Name
- Hepatitis B immune globulin
- Accession Number
- DB05276
- Description
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine.
HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Protein Based Therapies
Polyclonal antibody (pAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- HBIG
- Hepatitis B immune globulin
- Hepatitis B immune globulin (human)
- Hepatitis B immune globulin human
- Hepatitis B immunoglobulin (human)
- Human hepatitis B immunoglobulin
- Human hepatitis B virus immune globulin
- Human hepatitis-B immunoglobulin
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Target Actions Organism UHBsAg Not Available HBV - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Hepatitis B Immune Globulin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Hepatitis B Immune Globulin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Hepatitis B Immune Globulin. Alirocumab The risk or severity of adverse effects can be increased when Hepatitis B Immune Globulin is combined with Alirocumab. Ansuvimab The risk or severity of adverse effects can be increased when Hepatitis B Immune Globulin is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Hepatitis B Immune Globulin is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Hepatitis B Immune Globulin is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hepatitis B Immune Globulin. Asfotase alfa The risk or severity of adverse effects can be increased when Hepatitis B Immune Globulin is combined with Asfotase alfa. Atezolizumab The risk or severity of adverse effects can be increased when Hepatitis B Immune Globulin is combined with Atezolizumab. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image H-big Liquid Intramuscular Abbott 1988-12-31 1997-08-18 Canada 
HepaGam B Injection, solution 312 [iU]/1mL Intramuscular; Intravenous Aptevo Biotherapeutics Llc 2016-07-01 Not applicable US 
HepaGam B Injection, solution 50 mg/1mL Intramuscular; Intravenous Cangene BioPharma, LLC 2010-08-01 2018-02-28 US HepaGam B Injection, solution 312 [iU]/1mL Intramuscular; Intravenous Apotex Corporation 2008-12-01 2012-12-31 US HepaGam B Injection 312 [iU]/1mL Intramuscular; Intravenous Saol Therapeutics Inc. 2018-06-20 Not applicable US HepaGam B Solution 312 unit Intramuscular; Intravenous Saol Therapeutics Research Limited 2007-08-13 Not applicable Canada HepaGam B Solution 312 [iU]/1mL Intramuscular; Intravenous Aptevo Biotherapeutics Llc 2016-07-01 Not applicable US HepaGam B Injection 312 [iU]/1mL Intramuscular; Intravenous Saol Therapeutics Inc. 2019-03-01 Not applicable US HepaGam B Injection, solution 312 [iU]/1mL Intramuscular; Intravenous Cangene bioPharma Inc. 2010-08-01 2018-02-28 US HepaGam B Injection, solution 312 [iU]/1mL Intramuscular; Intravenous Apotex Corporation 2008-12-01 2012-12-31 US
Categories
- ATC Codes
- J06BB04 — Hepatitis b immunoglobulin
- Drug Categories
- Amino Acids, Peptides, and Proteins
- Antiinfectives for Systemic Use
- Blood Proteins
- Globulins
- Human Immunoglobulin
- Immune Sera and Immunoglobulins
- Immunization, Passive
- Immunoglobulins
- Immunoproteins
- Passively Acquired Immunity
- Proteins
- Serum
- Serum Globulins
- Specific Immunoglobulins
- Virus Neutralization
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- XII270YC6M
- CAS number
- Not Available
References
- General References
- Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS: Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology. 1998 Jan;27(1):213-22. [PubMed:9425940]
- External Links
- PubChem Substance
- 347910055
- 26744
- ChEMBL
- CHEMBL2108512
- Wikipedia
- Hepatitis_B_immune_globulin
- AHFS Codes
- 80:04.00 — Serums
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Transplantation, Liver / Viral Hepatitis B 1 4 Completed Prevention Viral Hepatitis B 1 4 Completed Supportive Care Viral Hepatitis B 1 4 Recruiting Prevention Chronic Infection / Congenital Malformations / Fetal Malformation / Hepatitis B Infection / Viral sepsis 1 4 Unknown Status Treatment Transplantation, Liver / Viral Hepatitis B 1 3 Completed Prevention Hepatitis B Chronic Infection 1 3 Completed Prevention Transplantation, Liver / Viral Hepatitis B 1 3 Completed Prevention Viral Hepatitis B 1 3 Withdrawn Treatment Hepatitis B Chronic Infection 1 2 Completed Prevention Hepatitis B Chronic Infection 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution 180 U.I. Injection, solution 540 U.I. Injection, solution Intravenous 100 U.I. Injection, solution Intravenous 500 U.I. Injection, solution Intramuscular 200 IU/ml Injection, solution Intramuscular 100 IU/0.5ml Injection Intramuscular; Intravenous 312 [iU]/1mL Injection, solution Intramuscular; Intravenous 312 [iU]/1mL Injection, solution Intramuscular; Intravenous 50 mg/1mL Solution Intramuscular; Intravenous 312 [iU]/1mL Solution Intramuscular; Intravenous 312 unit Injection, solution Intramuscular; Intravenous 1560 iu/5ml Injection, solution Intramuscular; Intravenous 312 iu/1ml Injection, solution Intravenous 100 UI/2ML Injection, solution Intravenous 2000 U.I./40ML Injection, solution Intravenous 500 UI/10ML Solution Parenteral 50 IU/ml Injection Intravenous 50 iu/nl Solution, concentrate Intravenous 50 IU Liquid Intramuscular Injection 200 IU/ml Injection Intravenous 1000 iu/5ml Injection Intravenous 200 iu/1ml Injection, solution Intravenous 100 IU/mL Injection, solution Intramuscular 400 UI/2ML Injection Intramuscular 220 [iU]/1mL Injection, solution Intramuscular 220 IU/ml Solution Intramuscular Injection, solution Intramuscular 1000 UI/5ML Injection, solution Intramuscular 600 UI/3ML Injection, solution Intramuscular 312 IU/ml Injection, solution Intramuscular 1000 UI/3ML Injection, solution Intramuscular 180 U.I./1ML Injection, solution Intramuscular 540 U.I./3ML Solution Intramuscular 1000 IU Solution Intramuscular 180 IU Injection, powder, lyophilized, for solution Intravenous 5000 iu/100ml Injection, solution Intravenous 50 UI/ML Powder, for solution Intravenous 50 UI/ML Injection Intramuscular 1560 [iU]/5mL Injection Intramuscular 312 [iU]/1mL Liquid Intramuscular 1560 [iU]/5mL Liquid Intramuscular 312 [iU]/1mL Injection, solution Parenteral 50 IU/mL Injection, solution Intravenous 250 I.U./ML Injection, solution Intramuscular 180 UI/1ML Injection, solution Intramuscular 540 UI/3ML Powder, for solution Intravenous 2500 UI/50ML Powder, for solution Intravenous 500 U.I./10ML Injection, powder, for solution Parenteral 50 IU/ml Injection, solution Subcutaneous 500 UI Injection, solution Subcutaneous 500 IU Injection, solution Intravenous Solution Injection, solution Injection - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- HBV
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- S gene
- Uniprot ID
- Q69600
- Uniprot Name
- HBsAg
- Molecular Weight
- 25420.905 Da
Drug created on November 18, 2007 18:23 / Updated on February 24, 2021 23:07